1. Minimum and Optimal CA19-9 Response After Two Months Induction Chemotherapy in Patients With Locally Advanced Pancreatic Cancer A Nationwide Multicenter Study.
- Author
-
Seelen, Leonard W. F., Doppenberg, Deesje, Stoop, Thomas F., Nagelhout, Anne, Brada, Lilly J. H., Bosscha, Koop, Busch, Olivier R., Cirkel, Geert A., den Dulk, Marcel, Daams, Freek, van Dieren, Susan, van Eijck, Casper H. J., Festen, Sebastiaan, Koerkamp, Bas Groot, Mohammad, Nadia Haj, de Hingh, Ignace H. J. T., Lips, Daan J., Los, Maartje, de Meijer, Vincent E., and Patijn, Gijs A.
- Abstract
Objective: This nationwide multicenter study aimed to define clinically relevant thresholds of relative serum CA19-9 response after 2 months of induction chemotherapy in patients with locally advanced pancreatic cancer (LAPC). Background: CA19-9 is seen as leading biomarker for response evaluation in patients with LAPC, but early clinically useful cut-offs are lacking. Methods: All consecutive patients with LAPC after 4 cycles (m)FOLFIRINOX or 2 cycles gemcitabine-nab-paclitaxel induction chemotherapy ( ± radiotherapy) with CA19-9 ≥5 U/mL at baseline were analyzed (2015–2019). The association of CA19-9 response with median OS (mOS) was evaluated for different CA19-9 cut-off points. Minimum and optimal CA19-9 response were established via log-rank test. Predictors for OS were analyzed using COX regression analysis. Results: Overall, 212 patients were included, of whom 42 (19.8%) underwent resection. Minimum CA19-9 response demonstrating a clinically significant median OS difference (12.7 vs. 19.6 months) was seen at ≥ 40% CA19-9 decrease. The optimal cutoff for CA19-9 response was ≥ 60% decrease (21.7 vs. 14.0 mo, P = 0.021). Only for patients with elevated CA19-9 levels at baseline (n = 184), CA19-9 decrease ≥ 60% [hazard ratio (HR) = 0.59, 95% CI, 0.36–0.98, P = 0.042] was independently associated with prolonged OS, as were SBRT (HR = 0.42, 95% CI, 0.25–0.70; P = 0.001), and resection (HR = 0.25, 95% CI, 0.14–0.46, P < 0.001), and duration of chemotherapy (HR = 0.75, 95% CI, 0.69–0.82, P < 0.001). Conclusions: CA19-9 decrease of ≥60% following induction chemotherapy as optimal response cut-off in patients with LAPC is an independent predictor for OS when CA19-9 is increased at baseline. Furthermore, ≥40% is the minimum cut-off demonstrating survival benefit. These cut-offs may be used when discussing treatment strategies during early response evaluation. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF